Madrigal Pharmaceuticals Inc (MDGL)
308.71
+15.30
(+5.21%)
USD |
NASDAQ |
Dec 20, 16:00
307.91
-0.80
(-0.26%)
After-Hours: 20:00
Madrigal Pharmaceuticals Net Income (Quarterly): -106.96M for Sept. 30, 2024
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
Corcept Therapeutics Inc | 47.21M |
89bio Inc | -149.07M |
ADMA Biologics Inc | 35.91M |
Matinas BioPharma Holdings Inc | -4.275M |
Viking Therapeutics Inc | -24.94M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 62.18M |
Total Expenses (Quarterly) | 178.48M |
EPS Diluted (Quarterly) | -4.92 |
Enterprise Value | 5.852B |
Gross Profit Margin (Quarterly) | 96.54% |
Profit Margin (Quarterly) | -172.0% |
Earnings Yield | -8.14% |
Normalized Earnings Yield | -8.137 |